title: Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease.
abstract: The pathological development of diabetic kidney disease (DKD) might involve metabolic perturbations in kidney tissue. The present study was designed to detect the systematic alterations of renal cortex metabolites thereby exploring the related mechanisms of DKD development and fosinopril treatment. Based on combined gas chromatography/time-of-flight mass spectrometry (GC-TOF MS) and liquid chromatography/time-of-flight mass spectrometry (UPLC-TOF MS) data acquiring platform, we have performed a metabolomic analysis of perfused renal cortex samples from the diabetic rats induced by streptozocin and treated with or without fosinopril, a pharmacological inhibitor of angiotensin II converting enzyme (ACEI). We identified a number of abnormal metabolites in the diabetic kidney, including groups of amino acids, carbohydrates, polyols, lyso-phospholipids, glucuronides and other unidentified metabolites. Of them, an increase in intrarenal organic toxins including uremic toxins, glucuronides and glucotocixity-associated metabolites are highly correlated with diabetic kidney injury including 24h urinary protein levels and tubulointerstitial injury index. Treatment with fosinopril significantly attenuated diabetic kidney injury, and simultaneously blocked the intrarenal accumulation of these organic toxins, especially hippurate and glucuronides. These results indicate that intrarenal accumulation of organic toxins may be significant for the development of DKD and the related mechanisms deserve to be further investigated.
authors.affiliation: Department of Pharmacology, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
authors.forename: Tie
authors.initials: T
authors.lastname: Zhao
authors.forename: Haojun
authors.initials: H
authors.lastname: Zhang
authors.forename: Tingting
authors.initials: T
authors.lastname: Zhao
authors.forename: Xianglin
authors.initials: X
authors.lastname: Zhang
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Tingting
authors.initials: T
authors.lastname: Yin
authors.forename: Qionglin
authors.initials: Q
authors.lastname: Liang
authors.forename: Yiming
authors.initials: Y
authors.lastname: Wang
authors.forename: Guoan
authors.initials: G
authors.lastname: Luo
authors.forename: Huiyao
authors.initials: H
authors.lastname: Lan
authors.forename: Ping
authors.initials: P
authors.lastname: Li
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D017328:Fosinopril / Q000627:therapeutic use; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D006801:Humans; D006984:Hypertrophy / Q000473:pathology; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D055432:Metabolomics / Q000379:methods; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014118:Toxins, Biological / Q000378:metabolism*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D014118:Toxins, Biological; D017328:Fosinopril